The lactylation modification as a metabolic-epigenetic bridge: Research progress and prospects in renal fibrosis
Current Proteomics · 2026-06 · 23 (3) · 100124
DOI: 10.1016/j.curpro.2026.100124 ↗Kurz gefasst
Fachartikel in der Zeitschrift Current Proteomics, 2026-06. Verfasst von Chao Gu und 4 weiteren Autor:innen. Die Arbeit nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Hunan University of Chinese Medicine.
Abstract (Originalsprache)
Background
Chronic kidney disease (CKD) is a major global public health problem with a standardized global prevalence of 15–20%, and renal fibrosis serves as a common irreversible pathological feature of all progressive CKDs, ultimately leading to end-stage renal disease (ESRD). While metabolic reprogramming and epigenetic dysregulation have been identified as core interrelated mechanisms, current clinical interventions remain limited to symptomatic care due to the incomplete elucidation of the complex regulatory network involved. Role of lactylation Lactylation, a novel histone post-translational modification that uses lactate—a core glycolytic metabolite—as the substrate, establishes a direct molecular bridge between glycolytic metabolism and epigenetic regulation. This modification has emerged as a research hotspot in renal fibrosis, influencing metabolic states, inflammatory responses, and fibrogenesis by modulating protein function and key gene transcription. Research progress This review systematically elaborates on the theoretical basis of lactylation (discovery, molecular mechanism, and biological functions) and the core pathophysiological characteristics and regulatory mechanisms of renal fibrosis from the perspective of metabolic-epigenetic crosstalk. It systematically reviews the theoretical basis of lactylation and the research progress in regulating key pathological processes of renal fibrosis, including epithelial-mesenchymal transition (EMT), fibroblast activation, and inflammatory microenvironment regulation. Challenges and controversies The review summarizes the unresolved scientific controversies, methodological limitations, and technical challenges in this field, such as the lack of specific lactylases and the poor specificity of detection antibodies. Furthermore, the review discusses field-specific ethical frameworks and clinical translation barriers unique to metabolic-epigenetic research in nephrology. Future directions Potential therapeutic targets and key translational research directions are proposed. The review specifically highlights the influence of sex and age on lactylation dynamics and advocate for the development of selective modulators, non-invasive detection methods, and large-scale clinical cohort studies.
Conclusion
By integrating theoretical foundations, mechanistic insights, and ethical considerations, this review provides a comprehensive academic perspective for studying the metabolic-epigenetic regulatory network of renal fibrosis, laying a theoretical foundation for developing novel targeted therapeutic strategies.
Förderung
- Hunan University of Chinese Medicine
Zitieren
APA
Gu, C., Peng, Y., Peng, Y., Yang, B., & He, Z. (2026). The lactylation modification as a metabolic-epigenetic bridge: Research progress and prospects in renal fibrosis. Current Proteomics, 23(3), 100124. https://doi.org/10.1016/j.curpro.2026.100124
Vancouver
Gu C, Peng Y, Peng Y, Yang B, He Z. The lactylation modification as a metabolic-epigenetic bridge: Research progress and prospects in renal fibrosis. Current Proteomics. 2026;23(3):100124. doi:10.1016/j.curpro.2026.100124
BibTeX
@article{Gu2026,
author = {Gu, Chao and Peng, Yaping and Peng, Yajun and Yang, Biying and He, Zeyun},
title = {The lactylation modification as a metabolic-epigenetic bridge: Research progress and prospects in renal fibrosis},
journal = {Current Proteomics},
year = {2026},
volume = {23},
number = {3},
pages = {100124},
doi = {10.1016/j.curpro.2026.100124}
}
EUVIMED